Uppsala, Sweden, 12 October 2016
Beactica, the Swedish fragment-based drug discovery company, today announced its participation in a Marie Curie Initial Training Network (ITN). The ITN, called FRAGNET, is funded with 3.9 MEUR by the EU and aims to deliver 15 skilled early-stage researchers in the field of fragment-based drug discovery (FBDD).
“Training a new generation of drug hunters is essential to the future of the sector as well as Beactica’s growth” said Dr Per Källblad, CEO of Beactica, “We are delighted to join other leaders in the field of fragment-based drug discovery in the ITN FRAGNET; working with the best emerging talent will enable us to open up new frontiers in the field”
Over the last fifteen years, fragment-based drug discovery has proven to be an effective approach. To date, more than 30 drug candidates derived from fragments have entered the clinic, with two approved drugs and several more in late-stage clinical trials.
The FRAGNET network is composed of four academic beneficiaries (VU University Amsterdam, University of York, Hungarian Academy of Sciences, Universitat de Barcelona), four industrial beneficiaries (Beactica, Novartis, Vernalis, Zobio) as well as five partner organizations (GSK, Roche, Servier, IOTA, 24 Media Labs).
The official webpage of FRAGNET is www.fragnet.eu.
For additional information please contact Dr Per Källblad, Beactica CEO, +46 18 56 08 80.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interactions of molecules in order to generate novel therapeutics. As well as progressing its own drug discovery programmes in oncology and CNS, Beactica offers partnerships for fragment-based lead generation using its proprietary discovery platform. Founded in 2006 based on research carried out at Uppsala University, Beactica has established a reputation as the leader in fragment-based drug discovery using SPR biosensor technology.
Sign up for the Beactica newsletter to recieve our latest news and updates